Milestone Pharmaceuticals (MIST) Non-Current Assets (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Non-Current Assets came in at $1.5 million in Q1 2026, up 5.04% YoY from $1.4 million in Q1 2025, and down 9.7% on a QoQ basis from $1.6 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Non-Current Assets (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Non-Current Assets data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Non-Current Assets rose 5.04% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 17.07% YoY) and the FY2025 annual result came in at $1.6 million, up 4.26% from the prior year.
- Non-Current Assets retreated to $1.5 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $2.8 million in Q3 2022 to a low of $797000.0 in Q2 2022.
- A 5-year average of $1.8 million and a median of $1.7 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 208.76% — and 2025, when it tumbled 37.06%.
- Tracing MIST's Non-Current Assets over 5 years: stood at $2.7 million in 2022, then retreated by 18.13% to $2.2 million in 2023, then dropped by 28.3% to $1.6 million in 2024, then climbed by 4.26% to $1.6 million in 2025, then fell by 9.7% to $1.5 million in 2026.
- The last three Non-Current Assets figures came in at $1.5 million (Q1 2026), $1.6 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 2.03 Mn |
| Dec 31, 2023 | 2.19 Mn |
| Sep 30, 2023 | 2.32 Mn |
| Jun 30, 2023 | 2.45 Mn |
| Mar 31, 2023 | 2.57 Mn |
| Dec 31, 2022 | 2.68 Mn |
| Sep 30, 2022 | 2.85 Mn |
| Jun 30, 2022 | 797,000.00 |
| Mar 31, 2022 | 833,000.00 |
| Dec 31, 2021 | 926,000.00 |
| Sep 30, 2021 | 1.02 Mn |